evidence:  Patients allocated to receive thalidomide also received that drug as maintenance therapy. The trial failed to detect a difference in overall survival (hr: 0.68; 95% ci: 0.38 to 1.22; p = 0.19), but the trial design did not have statistical power sufficient to address that outcome measure
intervention: thalidomide also received that drug as maintenance therapy
comparator: baseline
outcome: the 2-year event-free survival